Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Old and new heparins.

Cosmi B, Palareti G.

Thromb Res. 2012 Mar;129(3):388-91. doi: 10.1016/j.thromres.2011.11.008. Epub 2011 Dec 2. Review.

PMID:
22137740
2.

Alternatives to standard unfractionated heparin for pediatric hemodialysis treatments.

Davenport A.

Pediatr Nephrol. 2012 Oct;27(10):1869-79. doi: 10.1007/s00467-012-2129-5. Epub 2012 Feb 29. Review.

3.

Direct inhibitors of coagulation proteins - the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy?

Laux V, Perzborn E, Heitmeier S, von Degenfeld G, Dittrich-Wengenroth E, Buchmüller A, Gerdes C, Misselwitz F.

Thromb Haemost. 2009 Nov;102(5):892-9. doi: 10.1160/TH09-02-0134. Review.

PMID:
19888525
4.

-Anticoagulant drugs-.

Gulba DC.

Herz. 1996 Feb;21(1):12-27. Review. German.

PMID:
8647576
5.

New oral anticoagulants in development.

Weitz JI.

Thromb Haemost. 2010 Jan;103(1):62-70. doi: 10.1160/TH09-07-0434. Epub 2009 Oct 26. Review.

PMID:
20062934
6.

Heparin and low-molecular-weight heparin.

Gray E, Mulloy B, Barrowcliffe TW.

Thromb Haemost. 2008 May;99(5):807-18. doi: 10.1160/TH08-01-0032. Review.

PMID:
18449410
7.

[Preventing venous thromboembolism].

Encke A, Haas S.

Chirurg. 2007 Feb;78(2):110, 112-8. Review. German.

PMID:
17265054
8.

Pharmacology of the low-molecular-weight heparins.

Turpie AG.

Am Heart J. 1998 Jun;135(6 Pt 3 Su):S329-35. Review.

PMID:
9628446
9.

Guide to anticoagulant therapy: Heparin : a statement for healthcare professionals from the American Heart Association.

Hirsh J, Anand SS, Halperin JL, Fuster V; American Heart Association.

Circulation. 2001 Jun 19;103(24):2994-3018. Review. No abstract available.

10.

Low-molecular-weight heparins for the prevention and treatment of venous thromboembolism.

Ornstein DL, Hong-Dice YG, Papini JR.

Mil Med. 2001 Jul;166(7):593-601. Review.

PMID:
11469031
11.

Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?

Fareed J, Iqbal O, Cunanan J, Demir M, Wahi R, Clarke M, Adiguzel C, Bick R.

Int Angiol. 2008 Jun;27(3):176-92. Review.

PMID:
18506123
12.

Beyond heparin and warfarin: the new generation of anticoagulants.

Weitz JI, Linkins LA.

Expert Opin Investig Drugs. 2007 Mar;16(3):271-82. Review.

PMID:
17302522
13.

Orally active heparin and low-molecular-weight heparin.

Pineo GF, Hull RD, Marder VJ.

Curr Opin Pulm Med. 2001 Sep;7(5):344-8. Review.

PMID:
11584187
14.

New anticoagulants.

Agnelli G, Becattini C.

Semin Thromb Hemost. 2006 Nov;32(8):793-802. Review.

PMID:
17171592
15.

Atrial fibrillation and dabigatran: has the time come to use new anticoagulants?

Escobar C, Barrios V, Jimenez D.

Cardiovasc Ther. 2010 Oct;28(5):295-301. doi: 10.1111/j.1755-5922.2010.00216.x. Epub 2010 Aug 16. Review.

PMID:
20718760
16.

New parenteral anticoagulants in development.

Gómez-Outes A, Suárez-Gea ML, Lecumberri R, Rocha E, Pozo-Hernández C, Vargas-Castrillón E.

Ther Adv Cardiovasc Dis. 2011 Feb;5(1):33-59. doi: 10.1177/1753944710387808. Epub 2010 Nov 2. Review.

PMID:
21045018
17.

[Prevention with low dosage heparin. Selective or general?].

Schmitz-Huebner U.

Internist (Berl). 1997 Jul;38(7):667-71. Review. German. No abstract available.

PMID:
9333600
18.

Perspectives on antithrombotic agents: from unfractionated heparin to new antithrombotics.

Agnelli G, Sonaglia F.

Haematologica. 2002 Jul;87(7):757-70. Review.

19.

[Treatment and prophylaxis of deep venous thrombosis with low molecular weight heparins (meta-analysis of clinical trials)].

Valiukiene L, Naudziūnas A, Unikauskas A.

Medicina (Kaunas). 2003;39(4):352-8. Review. Lithuanian.

20.

Issues in the utilization of low molecular weight heparins.

O'Shea SI, Ortel TL.

Semin Hematol. 2002 Jul;39(3):172-8. Review.

PMID:
12124679
Items per page

Supplemental Content

Write to the Help Desk